Frazer, Ian H. *


The University of Queensland 
Faculty of Medicine
TRI , 37 Kent St
Woolloongabba, Queensland, Australia 4102


Persisting infections with “high risk” human papillomaviruses (HPVs) are responsible for about 5% of the global cancer burden. Vaccines to prevent infection with two high risk HPVs, HPV16 and HPV18, based on HPV virus-like particles produced using recombinant DNA in yeast or insect cells and adjuvanted with alum, have been developed. These have been administered to over 100 million women worldwide over the last 10 years. They have proven safe and >95% effective at preventing persisting infection with these virus types, and resulting pre-malignant disease, in large scale trials. Recent data from Australia confirms that significant reduction in HPV associated disease has followed introduction in 2007 of universal immunisation of 12 year old girls and, more recently, of 12 year old  boys. Virus like particles have become the basis of many other vaccines now in development. Key questions remaining to be answered concern delivery of HPV vaccines in the countries with the highest burden of cervical cancer,  duration of protection, efficacy for prevention of cancers other than cervical cancer, and ability to broaden extent of protection by inclusion of further high risk HPV types. Cheaper, simpler technology for development of VLP based vaccines will assist with their further deployment.


Biographic Details

Ian Hector Frazer AC
Professor, Faculty of Medicine
The University of Queensland, Australia
Phone: +61 7 3443 6962 Cell +61 413 733248 E-mail:
Research interests: Cancer Immunotherapy, vaccine development